Clinical Trials Logo
  1. Home
  2. Hypereosinophilic Syndrome
  3. NCT04965636

Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) — SPHERE  

Hypereosinophilic Syndrome Clinical Trial

Official title:
A Phase 3, 52-week, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Mepolizumab SC in Participants Aged 6 to 17 Years With Hypereosinophilic Syndrome

Clinical Trial Summary

The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04965636
Study type Interventional
Source GlaxoSmithKline
Contact US GSK Clinical Trials Call Center
Phone 877-379-3718
Email GSKClinicalSupportHD@gsk.com
Status Recruiting
Phase Phase 3
Start date August 24, 2022
Completion date September 16, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05334368 - Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial Phase 3
Recruiting NCT00044304 - Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome Phase 2
Completed NCT00097370 - Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome Phase 3
Completed NCT00171912 - Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Phase 2
Terminated NCT00171860 - A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome Phase 2
Recruiting NCT02581514 - Eosinophilia Diagnosis N/A
Completed NCT00787384 - Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes Phase 2
Recruiting NCT03801434 - Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders Phase 2
Completed NCT00255346 - Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Phase 2
Completed NCT03306043 - A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 Phase 3
Recruiting NCT04018118 - Natural History of Hypereosinophilia and Hypereosinophilic Syndromes
Completed NCT02836496 - Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Phase 3
Completed NCT00086658 - Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) Phase 3
Recruiting NCT00276926 - Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias Phase 2
Active, not recruiting NCT02101138 - Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome Phase 2
Recruiting NCT00091871 - A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Completed NCT01713504 - Identification of New Markers in the Hypereosinophilic Syndrome N/A
Completed NCT00017862 - Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Phase 2
Completed NCT00038675 - Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate N/A
Terminated NCT00230334 - Phase II Gleevec Idiopathic Hypereosinophilic Syndrome Phase 2